by Truveta staff | Sep 19, 2024 | Research
Overall, the rate of hospitalizations associated with respiratory viruses remained stable throughout August 2024, with no change compared to July 2024. For infants and children aged 0-4 years old, respiratory virus-associated hospitalizations increased significantly...
by Truveta staff | Sep 11, 2024 | Research
The overall trends of hospitalizations associated with viral gastroenteritis – norovirus and rotavirus – show a steady decrease over the last few months, leading to a rate of 0.04% in August 2024 in the overall population. However, we see first indicators that the...
by Truveta News | Sep 4, 2024 | News
The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington’s School of Pharmacy has partnered with Truveta to use its electronic health record (EHR) data to drive comparative, cost-effectiveness, and outcomes research....
by Truveta staff | Jul 30, 2024 | Technology
In this blog I will discuss our approach to scaling our AI technologies across multiple dimensions while controlling development costs, operational costs, and assuring stability. LLMs are a powerful new technology, but they also have large development, operational,...
by Truveta Research | Jul 8, 2024 | Research
Truveta Research’s comparative effectiveness study exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide (Mounjaro) has been published in JAMA Internal Medicine. Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications,...
